Health Condition 1: L811- Chloasma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Female patient aged 20 to 50 years old with melasma
Exclusion criteria
Exclusion criteria: Consumption of antioxidants in last 3 months Use of isotretinoin in past 6 months Active inflammatory acne lesions Drugs causing photosensitivity and hyperpigmentation as epileptic drugs Antimalaria and tetracycline Pregnancy Patients who have undergone treatment recently with other modalities in past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Measurement of efficacy of modalities on the basis of quartile grading score 2.Modified Melasma Area and Severity Index Score 3.Patient satisfaction using Likert Satisfaction ScaleTimepoint: at baseline every 4 weeks at end of 16 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| side effects of topical Tranexamic 5% gel and topical Isobioniacinamide cysteamine complex in treatment of melasmaTimepoint: at baseline every 4 weeks at end of 16 weeks | — |
Countries
India
Contacts
Sri Devaraj Urs Medical College, Tamaka, Kolar